The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the end of recruitment of all participants.
We are pleased that after the long COVID lockdown we were also able to visit the East African sites to touch base and to discuss the conduct of the trial and potential improvements. We thank all centres for their warm welcome and their hospitality during our stay and hope to meet more often in person again.
